This event will discuss the many roles of bacteriophages, ranging from fundamental biological research to their use in medical and industrial biotechnologies. Topics will include uses of phages for therapeutics, food manufacture, delivery vectors, drivers of microbiota structure reporters of microbiome diversity, and their role on the environment.

This event has [CPD accreditation](https://www.cpd.ac.uk/).

Hashtag: #Phage2015
Table of Contents

Day 1: Bacteriophage Biology

Introduction by the Chair .............................................................................................................. 6
Regulation of replication of Shiga toxin-converting bacteriophages ................................................. 6
10:40 – 10:50 INVESTIGATION OF BACTERIAL RESISTANCE TO PSEUDOMONAS AERUGINOSA PHAGE
   AB26, A NOVEL PA73-LIKE PHAGE ......................................................................................... 6
Working collaboratively to jump-start phage therapy ................................................................. 6
Bacteriophages for healthy living ..................................................................................................... 6
Bacteriophage-Derived Biomaterials for the Targeting of Pathogenic Bacteria ................................. 6
Oral Presentations ........................................................................................................................... 6
12:10 – 12:20 A CHANGE IN PHAGE TYPE DURING AN OUTBREAK OF ESCHERICHIA COLI O157 IS
   COUPLED WITH A BROAD RANGE OF GENOMIC CHANGES DURING A SHORT TIME FRAME .... 6
12:20 – 12:30 SELECTIVE PRESSURE IMPOSED ON PSEUDOMONAS AERUGINOSA BY BACTERIOPHAGES
   .................................................................................................................................................. 6
Crystal structures of the Fibre Proteins of Bacteriophage T4, T5 and T7 ........................................ 6
Oral Presentations ........................................................................................................................... 6
13:40 – 13:50 P100 INSENSITIVE L.MONOCYTOGENES PLANT ISOLATES AND INFLUENCE OF
   ENVIRONMENTAL FACTORS ON PHAGE-BACTERIA INTERACTION, ON EFFICACY AND SURVIVAL OF THE
   PHAGE P100 .................................................................................................................................. 6
13:50 – 14:00 INFERRING BACTERIOPHAGE INFECTION STRATEGIES FROM GENOME SEQUENCE:
   ANALYSIS OF BACTERIOPHAGE 7-11 AND RELATED PHAGES .................................................. 6
14:00 – 14:10 OPTIMIZING PROTOCOLS FOR EXTRACTION OF BACTERIOPHAGES PRIOR METAGENOMIC
   ANALYSES OF VIRAL COMMUNITIES IN THE HUMAN GUT ....................................................... 6
Control of recombination directionality by serine integrases ....................................................... 6
A Flood of Bacillus phages: discovering new science and new scientists ..................................... 6
Developing bacteriophage-based assays to detect viable Mycobacteria ....................................... 6
Oral Presentations ........................................................................................................................... 6
15:30 – 15:40 PROPHAGES DETERMINE PHENOTYPIC PLASTICITY OF LACTOCoccus LACTIS HOST .... 6
15:40 – 15:40 ANTIBIOTIC RESISTANCE GENES FOUND IN VIRAL METAGENOMES COME FROM
   BACTERIA, NOT VIRUSES ........................................................................................................... 6
15:50 – 16:00 PRIMARY ISOLATION STRAIN DETERMINES BOTH PHAGE TYPE AND RECEPTORS
   RECOGNISED BY CAMPYLOBACTER JEUNI BACTERIOPHAGES ............................................ 6
Resolution of branched DNA structures by phage endonucleases ............................................... 6
Leveraging bacteriophages for high speed, enrichment-free environmental monitoring ................ 6

Day 2: Bacteriophage Therapy Part 1

Introduction by the Chair ............................................................................................................... 8
Recognition is the first step - harnessing phage-host interaction for rapid diagnostics .................. 8
Extensive bacteriophage mediated horizontal gene transfer during Staphylococcus aureus colonization
   in vivo ............................................................................................................................................. 8
European Implementation of Bacteriophage Therapy: Impact of Medicinal Product Legislation on
   Tailored Hospital Care .................................................................................................................. 8
Day 3: Bacteriophage Therapy Part 2

Introduction by the Chair
Stx prophage control of host phenotypes
GMP manufacture of phages for clinical trial
Modern ideas for combating bacteria
Overview on Yersinia phages and update on phage therapy initiative in Finland
Oral Presentations
12:00 – 12:15 DEVELOPING PHAGE THERAPY TO TREAT CANINE SKIN INFECTION (PYODERMA) CAUSED BY STAPHYLOCOCCUS PSEUDINTERMEDIUS

Discussion session
Oral Presentations
14:45- 15:00 SYNERGY BETWEEN BACTERIOPHAGE-ENCODED PEPTIDOGLYCAN HYDROLASES AND HIGH PRESSURE ON THE INACTIVATION OF LISTERIA MONOCYTOGENES AND STAPHYLOCOCCUS AUREUS

Bacteriophage lytic enzymes with a broad antibacterial spectrum
Monolith chromatography for fast and scalable phage purification

About the Speakers
Grzegorz Wegryn
Martha Clokie
Elizabeth Martin Kutter
Alexander “Sandro” Sulakvelidze
Stephane Evoy
Mark van Raaij
Paul CM Fogg
Louise Temple
Catherine E.D. Rees
Gary Sharples
Frequently asked questions about our events

Can I have a CPD certificate?

Is there WIFI?

I don’t want my photograph on any Euroscicon promotional material

How can I keep up to date with Euroscicon Events?

Can I have the speakers slides?

Can I have a notepad?

Is the delegate list available?

Frequently asked questions about our events

Discussion Sessions

Session breaks

Lunch

- All the chicken in our lunch buffet is Halal
- We have a number of dishes that are gluten free
- We have a range of vegetarian dishes which are separated from the meat and fish dishes

Day 1

Day 2

Day 3

Heather E. Allison,

Zuzanna Druis-Kawa,

Mikael Skurnik,

Magdalena Plotka,

Tony Hitchcock,

Rok Sekirnik,

Michael Koeris,

Jodi A Lindsay,

Gilbert Verbeken,

Steven Hagens,

David P Trudil,

Mireille Ansaldi,

Olivia McAuliffe,

Bin Zhu,
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 09:45</td>
<td>Exhibitions open</td>
<td>Registration and Refreshments</td>
</tr>
<tr>
<td>09:45 – 10:00</td>
<td>Introduction by the Chair</td>
<td>Professor George Salmond, University of Cambridge, Cambridge, UK</td>
</tr>
<tr>
<td>10:00 – 10:20</td>
<td>Oral Presentations</td>
<td>Professor Grzegorz Wargacz, Department of Molecular Biology, University of Gdansk, Poland</td>
</tr>
<tr>
<td>10:20 – 10:40</td>
<td>Ecology, evolution and applications of bacteriophages in bacterial pathogens with environmental reservoirs</td>
<td>Dr. Martha Clokie, Reader in Microbiology, Department of Infection, Immunity and Inflammation, Medical Sciences Building, University of Leicester</td>
</tr>
<tr>
<td>10:40 – 10:50</td>
<td>Oral Presentations</td>
<td>Dr. Elizabeth Martin Kutter, Lab I, The Evergreen State College, Olympia, USA</td>
</tr>
<tr>
<td>10:50 – 11:10</td>
<td>Session Break</td>
<td>Speakers’ photo, Refreshments, Poster viewing, Sponsors exhibition</td>
</tr>
<tr>
<td>11:10 – 11:30</td>
<td>Oral Presentations</td>
<td>Dr Alexander Sulakvelidze, Intralytix, Inc, Baltimore, USA</td>
</tr>
<tr>
<td>11:30 – 11:50</td>
<td>Oral Presentations</td>
<td>Professor. Stephane Evoy, University of Alberta, Canada</td>
</tr>
<tr>
<td>11:50 – 12:10</td>
<td>Oral Presentations</td>
<td>Lunch, Poster viewing, Sponsors exhibition</td>
</tr>
<tr>
<td>12:10 – 12:30</td>
<td>Oral Presentations</td>
<td>Dr Mark van Raaij, Centro Nacional de Biotecnologia-CSIC, Madrid, Spain</td>
</tr>
<tr>
<td>12:30 – 13:20</td>
<td>Oral Presentations</td>
<td>Crystal structures of the Fibre Proteins of Bacteriophage T4, T5 and T7</td>
</tr>
<tr>
<td>13:20 – 13:40</td>
<td>Oral Presentations</td>
<td>Dr. Elizabeth Martin Kutter, Lab I, The Evergreen State College, Olympia, USA</td>
</tr>
<tr>
<td>13:40 – 14:10</td>
<td>Oral Presentations</td>
<td>Dr Paul CM Fogg, University of York, Department of Biology, Wentworth Way, York, UK</td>
</tr>
<tr>
<td>14:10 – 14:30</td>
<td>Oral Presentations</td>
<td>Professor Louise Temple, James Madison University, Harrisonburg, Virginia, USA</td>
</tr>
<tr>
<td>14:30 – 14:50</td>
<td>Oral Presentations</td>
<td>Refreshments, Last poster viewing, Last Sponsors exhibition</td>
</tr>
<tr>
<td>14:50 – 15:10</td>
<td>Oral Presentations</td>
<td>Dr. Elizabeth Martin Kutter, Lab I, The Evergreen State College, Olympia, USA</td>
</tr>
<tr>
<td>15:10 – 15:30</td>
<td>Oral Presentations</td>
<td>Professor. Stephane Evoy, University of Alberta, Canada</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Oral Presentations</td>
<td>Dr. Michael Koeris, Founder, VP Business Development &amp;</td>
</tr>
</tbody>
</table>

**Day 1: Bacteriophage Biology**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 09:45</td>
<td>Exhibitions open</td>
<td>Registration and Refreshments</td>
</tr>
<tr>
<td>09:45 – 10:00</td>
<td>Introduction by the Chair</td>
<td>Professor George Salmond, University of Cambridge, Cambridge, UK</td>
</tr>
<tr>
<td>10:00 – 10:20</td>
<td>Oral Presentations</td>
<td>Professor Grzegorz Wargacz, Department of Molecular Biology, University of Gdansk, Poland</td>
</tr>
<tr>
<td>10:20 – 10:40</td>
<td>Ecology, evolution and applications of bacteriophages in bacterial pathogens with environmental reservoirs</td>
<td>Dr. Martha Clokie, Reader in Microbiology, Department of Infection, Immunity and Inflammation, Medical Sciences Building, University of Leicester</td>
</tr>
<tr>
<td>10:40 – 10:50</td>
<td>Oral Presentations</td>
<td>Dr. Elizabeth Martin Kutter, Lab I, The Evergreen State College, Olympia, USA</td>
</tr>
<tr>
<td>10:50 – 11:10</td>
<td>Session Break</td>
<td>Speakers’ photo, Refreshments, Poster viewing, Sponsors exhibition</td>
</tr>
<tr>
<td>11:10 – 11:30</td>
<td>Oral Presentations</td>
<td>Dr Alexander Sulakvelidze, Intralytix, Inc, Baltimore, USA</td>
</tr>
<tr>
<td>11:30 – 11:50</td>
<td>Oral Presentations</td>
<td>Professor. Stephane Evoy, University of Alberta, Canada</td>
</tr>
<tr>
<td>11:50 – 12:10</td>
<td>Oral Presentations</td>
<td>Lunch, Poster viewing, Sponsors exhibition</td>
</tr>
<tr>
<td>12:10 – 12:30</td>
<td>Oral Presentations</td>
<td>Dr Mark van Raaij, Centro Nacional de Biotecnologia-CSIC, Madrid, Spain</td>
</tr>
<tr>
<td>12:30 – 13:20</td>
<td>Oral Presentations</td>
<td>Crystal structures of the Fibre Proteins of Bacteriophage T4, T5 and T7</td>
</tr>
<tr>
<td>13:20 – 13:40</td>
<td>Oral Presentations</td>
<td>Dr. Elizabeth Martin Kutter, Lab I, The Evergreen State College, Olympia, USA</td>
</tr>
<tr>
<td>13:40 – 14:10</td>
<td>Oral Presentations</td>
<td>Dr Paul CM Fogg, University of York, Department of Biology, Wentworth Way, York, UK</td>
</tr>
<tr>
<td>14:10 – 14:30</td>
<td>Oral Presentations</td>
<td>Professor Louise Temple, James Madison University, Harrisonburg, Virginia, USA</td>
</tr>
<tr>
<td>14:30 – 14:50</td>
<td>Oral Presentations</td>
<td>Refreshments, Last poster viewing, Last Sponsors exhibition</td>
</tr>
<tr>
<td>14:50 – 15:10</td>
<td>Oral Presentations</td>
<td>Dr. Elizabeth Martin Kutter, Lab I, The Evergreen State College, Olympia, USA</td>
</tr>
<tr>
<td>15:10 – 15:30</td>
<td>Oral Presentations</td>
<td>Professor. Stephane Evoy, University of Alberta, Canada</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Oral Presentations</td>
<td>Dr. Michael Koeris, Founder, VP Business Development &amp;</td>
</tr>
<tr>
<td>Time</td>
<td>Title</td>
<td>Speaker</td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>16:40</td>
<td>Atomic structure of Bordetella phage BPP1 reveals a new topology of the highly conserved HK97-like fold</td>
<td>Professor Z. Hong Zhou, Ph.D., Electron Imaging Center for Nanomachines (EICN), CNSI and Dept of Microbiology, Immun. &amp; Mol. Genetics, UCLA, USA</td>
</tr>
<tr>
<td>17:00</td>
<td>Chairman's Summing Up</td>
<td>Close of Session</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Speaker/Details</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>09:00 – 09:45</td>
<td>Exhibitions open</td>
<td>Registration and Refreshments</td>
</tr>
<tr>
<td>09:45 – 10:00</td>
<td>Introduction by the Chair</td>
<td>Dr Darren Smith, Northumbria University, School of Life Sciences, Newcastle upon Tyne, United Kingdom</td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td>Recognition is the first step - harnessing phage-host interaction for rapid diagnostics</td>
<td>Professor. Dr. Martin J. Loessner, ETH Zurich, Institute of Food, Nutrition and Health, Zurich, Switzerland</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
<td>Extensive bacteriophage mediated horizontal gene transfer during Staphylococcus aureus colonization in vivo</td>
<td>Dr Jodi A Lindsay, PhD, St George’s, University of London, London, UK</td>
</tr>
<tr>
<td>11:00 – 11:30</td>
<td>Session Break</td>
<td>Speakers' photo, Refreshments, Poster viewing, Sponsors exhibition</td>
</tr>
<tr>
<td>11:30 – 12:00</td>
<td>European Implementation of Bacteriophage Therapy: Impact of Medicinal Product Legislation on Tailored Hospital Care</td>
<td>Dr Gilbert Verbeken, Human Cell- and Tissue Banks, Queen Astrid Military Hospital, Brussels, Belgium</td>
</tr>
</tbody>
</table>
| 12:00 – 12:30 | Oral Presentations                                                   | 12:00 – 12:15 CHARACTERIZATION OF THE CYSTEINE- HISTIDINE-DEPENDENT AMIDOHYDROLASE/PEPTIDASE DERIVED FROM THE STAPHYLOCOCCAL PHAGE K ENDOLYSIN  
A. Coffey, R. Keary, M. Sanz Gaitero, M. van Raaij, R.P. Ross, C. Hill, J. O'Mahony, O. McAuliffe  
Department of Biological Sciences, Cork Institute of Technology, Bishopstown, Cork, Ireland  
12:15 – 12:30 CHARACTERIZATION OF BACILLUS SUBTILIS PROPHAGE SPβ GENE FOR PHAGE ABORTIVE INFECTION  
T. Yamamoto, N. Obana, N. Nomura and K. Nakamura  
Faculty of Life and Environmental Sciences, University of Tsukuba, 1-1 Tennodai, Tsukuba City, Ibaraki 305-8572, Japan |
| 12:30 – 13:30 | Session Break                                                        | Lunch, Poster viewing, Sponsors exhibition                                        |
| 13:30 – 14:00 | Developing bacteriophage-based products for bio-control of unwanted bacteria in foodstuffs, animal health and human applications - possibilities and challenges | Dr Steven Hagens, PhD, Chief Scientific Officer, The Netherlands                   |
| 14:00 – 14:30 | Translating Bacteriophage and Lytic enzymes to uses for control of bacteria in environmental, human and animal applications | Dr David P Trudil, NHDetect Corp & Eliava Institute of Bacteriophage, Reisterstown, MD, USA |
| 14:30 – 14:45 | Oral Presentations                                                   | 14:30 – 14:45 PHAGE SELECTION RESTORES ANTIBIOTIC SENSITIVITY IN A DRUG-RESISTANT BACTERIAL PATHOGEN  
Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT USA |
| 14:45 – 15:15 | Session Break                                                        | Refreshments, Last poster viewing, Last Sponsors exhibition                      |
| 15:15 – 15:45 | Prophage maintenance in Enterobacteria                               | Dr Mireille Ansaldi, Aix Marseille Université, CNRS – Marseille, France          |
| 15:45 – 16:15 | Assessment of the bacteriophage ΦCD6356 and its biologically-active endolysin as novel antimicrobials targeting Clostridium difficile | Dr Olivia McAuliffe, Teagasc Food Research Centre, Cork, Ireland                 |
| 16:15 – 16:45 | Novel polymerases from marine phages                                 | Dr. Bin Zhu, Research Fellow, Harvard Medical School Boston, MA, USA             |
| 16:45 - 17:00 | Chairman's Summing Up                                                | Close of Session                                                                |
### Day 3: Bacteriophage Therapy Part 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 09:45</td>
<td>Exhibitions open</td>
<td>Registration and Refreshments</td>
</tr>
<tr>
<td>09:45 – 10:30</td>
<td>Introduction by the Chair</td>
<td><strong>Dr. Heather E. Allison</strong>, University of Liverpool, BioSciences Building, Crown Street, Liverpool, United Kingdom</td>
</tr>
<tr>
<td></td>
<td><strong>Stx prophage control of host phenotypes</strong></td>
<td><strong>Tony Hitchcock</strong>, Technology Director, Cobra Biologics, Newcastle, UK</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
<td>GMP manufacture of phages for clinical trial</td>
<td><strong>Dr Zuzanna Drulis-Kawa</strong> Ph.D., Institute of Genetics and Microbiology, University of Wroclaw, Poland</td>
</tr>
<tr>
<td>11:00 – 11:30</td>
<td>Modern ideas for combating bacteria</td>
<td><strong>Dr Mikael Skurnik</strong>, Ph.D., Professor of Bacteriology, University of Helsinki, Finland</td>
</tr>
<tr>
<td>11:30 – 12:00</td>
<td>Session Break</td>
<td>Speakers' photo, Refreshments, Poster viewing, Sponsors exhibition</td>
</tr>
<tr>
<td>12:00 – 12:30</td>
<td>Overview on Yersinia phages and update on phage therapy initiative in Finland</td>
<td><strong>Dr Mikael Skurnik</strong>, Ph.D., Professor of Bacteriology, University of Helsinki, Finland</td>
</tr>
<tr>
<td>12:30 – 12:45</td>
<td>Oral Presentations</td>
<td></td>
</tr>
<tr>
<td>12:00 – 12:15</td>
<td><strong>DEVELOPING PHAGE THERAPY TO TREAT CANINE SKIN INFECTION (PYODERMA) CAUSED BY STAPHYLOCOCCUS PSEUDINTERMEDIUS</strong></td>
<td><strong>M. Breteau</strong>, A. Moodley, F. Vogensen, E. Wellington, D. Hodgson <strong>School of Life Sciences, University of Warwick, Coventry, CV4 7AL</strong></td>
</tr>
<tr>
<td>12:45 – 13:00</td>
<td>Session Break</td>
<td>Lunch, Poster viewing, Sponsors exhibition</td>
</tr>
<tr>
<td>13:45 – 14:45</td>
<td>Discussion Break</td>
<td></td>
</tr>
<tr>
<td>14:45 – 15:15</td>
<td>Oral Presentations</td>
<td></td>
</tr>
<tr>
<td>14:45 – 15:00</td>
<td><strong>SYNERGY BETWEEN BACTERIOPHAGE-ENCODED PEPTIDOGLYCAN HYDROLASES AND HIGH PRESSURE ON THE INACTIVATION OF LISTERIA MONOCYTOGENES AND STAPHYLOCOCCUS AUREUS</strong></td>
<td><strong>T.J. van Nassau</strong>, C.A. Lenz, A.S. Scherzinger and R.F. Vogel <strong>Lehrstuhl für Technische Mikrobiologie, Technische Universität München, Gregor-Mendel-Str. 4, 85354 Freising, Germany</strong></td>
</tr>
<tr>
<td>15:00 – 15:15</td>
<td><strong>MATURATION OF THE BACTERIOPHAGE SPP1 AND CONFORMATIONAL CHANGES IN THE COAT PROTEIN REVEALED BY FITTING INTO CRYO-EM DENSITY</strong></td>
<td><strong>Athanasios Ignatiou</strong>, Daniel Clare, Rudi Lurz, Sandrine Brasiles, Maya Topp, Paulo Tavares, Elena Orlova <strong>Department of Biological Sciences, Birkbeck College, Institute for Structural and Molecular Biology, London, UK;</strong> <strong>Max Planck Institute for Molecular Genetics, Ihnstraße 63–73, D-14195 Berlin, Germany.</strong> <strong>Unité de Virologie Moléculaire et Structurale, Centre National de la Recherche Scientifique UPR3296, Centre de Recherche de Gif, Bâtiment 14B, CNRS, 91198 Gif-sur-Yvette, France</strong></td>
</tr>
<tr>
<td>15:15 – 15:45</td>
<td>Session Break</td>
<td>Speakers' photo, Refreshments, Poster viewing, Sponsors exhibition</td>
</tr>
<tr>
<td>15:45 – 16:15</td>
<td><strong>Bacteriophage lytic enzymes with a broad antibacterial spectrum.</strong></td>
<td><strong>Dr Magdalena Plotka</strong>, Department of Microbiology, University of Gdansk, Gdansk, Poland</td>
</tr>
<tr>
<td>16:15 – 16:45</td>
<td><strong>Monolith chromatography for fast and scalable phage purification</strong></td>
<td><strong>Dr Rok Sekirnik</strong>, BIA Separations, Slovenia</td>
</tr>
<tr>
<td>16:45 – 17:00</td>
<td><strong>Chairman’s Summing Up</strong></td>
<td><strong>Close of Meeting</strong></td>
</tr>
</tbody>
</table>
About the Speakers

Day 1

Grzegorz Wegrzyn, has graduated from University of Gdansk (Poland), where he also obtained PhD degree. He was a post-doctoral fellow at University of Nottingham (UK) and University of California at San Diego (USA). He is now a head of Department of Molecular Biology at University of Gdansk. Fields of his research and scientific interest are molecular biology and biotechnology of extrachromosomal genetic elements, mechanisms of regulation of DNA replication, and control of gene expression. He is an author of over 250 articles in international journals, and editor of some of them, including FEMS Microbiology Reviews, Microbial Cell Factories, and Plasmid.

Martha Clokie, Reader in Microbiology, Department of Infection, Immunity and Inflammation, Medical Sciences Building, University of Leicester

Elizabeth Martin Kutter, Lab I, The Evergreen State College, Olympia, WA, USA
Betty Kutter has worked with phage since 1963; her PhD explored the transition from host to viral metabolism after T4 infection and the role of 5HMdC. She came to Evergreen in 1972, and led the international team sequencing T4 after a 1978-79 sabbatical with Bruce Alberts. She has put on 20 CSH-style biennial phage meetings, which were responsible for the 1983 and 1994 ASM T4 books. They expanded to include all aspects of phage ecology, molecular biology and applications, with a special interest in phage therapy and agricultural applications sparked during 4 months she spent in the Soviet Union in 1990.

Alexander “Sandro” Sulakvelidze, Intralytix, Inc, Baltimore, USA
Dr Sulakvelidze is Vice-President for R&D and Chief Scientist of Intralytix, Inc. He is an internationally recognized expert in phage technology. Dr. Sulakvelidze has published extensively on the subject of phage therapy, and he is the author of several issued and pending patents. Dr. Sulakvelidze also co-edited a major book about bacteriophages, which was published by the CRC Press in 2005. Dr. Sulakvelidze’s research has been featured in several magazines and in various radio programs and television documentaries. In addition to his responsibilities as Editor-in-Chief of Bacteriophage, Dr. Sulakvelidze serves as an ad hoc reviewer for various scientific journals and for several funding agencies.

Stephane Evoy, University of Alberta, Canada

Mark van Raaij, Lab 20B, Madrid, Spain
Mark van Raaij studied Chemistry at the University of Leiden and obtained his PhD from Cambridge University. After postdoctoral work at the EMBL Grenoble outstation and Leiden University, he moved to Spain to start his own research group. At the Centro Nacional de Biotecnologia of the Spanish National Research Council, his group studies the structures of adenovirus fibres, bacteriophage proteins, enzyme-inhibitor complexes and antibiotic peptide structures.

Paul CM Fogg, University of York, Department of Biology, Wentworth Way, York, UK
Dr Paul Fogg attained his PhD at the University of Liverpool on the phenomenon of Stx-phage multiple lysogeny and the consequent potential for disease, before taking up a postdoctoral post at the University of British Columbia, Vancouver, to study horizontal gene transfer by the novel virus-like gene transfer agents (GTAs). Paul is currently working with Prof. Margaret Smith, at the University of York, on the production and optimization of a serine integrase directional recombination (SIDR) toolkit for application in synthetic biology.

Louise Temple, James Madison University, Harrisonburg, Virginia, USA
Dr. Temple has been an undergraduate science educator for over 20 years, focusing on original research as a vehicle for training young scientists. She directs a program for entering college freshmen in which they isolate unique phages from soil that infect species of Bacillus. In addition to bacteriophage genomics and biology, she investigates the pathogenesis of Bordetella avium, a pathogen of turkeys, related to B. pertussis, which infects humans. With collaborators in the US, UK, and India, she is currently working to develop B. avium as a heterologous delivery system for important poultry pathogens such as bird flu.

Catherine E.D. Rees, Associate Professor in Microbiology, School of Biosciences, University of Nottingham, Sutton Bonnington Campus, Loughborough, LE12 5RD
Gary Sharples, studied microbiology (Glasgow) followed by a PhD in bacterial recombination (Nottingham). Work in Nottingham over 15 years largely focused on studying bacterial enzymes that target branched DNA molecules. The discovery that an E. coli resolvase, RusA, was encoded by a cryptic prophage sparked an interest in bacteriophage recombination. He has since worked on phage lambda as a model system, including structure-function analyses on Beta and Orf which initiate exchanges and Rap which resolves the resulting DNA branches. He is currently based at Durham University and has a keen interest in all aspects of bacterial and phage evolution.

Michael Koeris, Founder, VP Business Development & Operations, Sample6, Boston, US
Michael is a co-founder and COO of Sample6 Technologies, a Synthetic Biology startup aiming to improve the health and safety of global consumers. Sample6 is developing integrated systems that can quickly and easily detect harmful and unwanted bacteria in the food, healthcare, and other industries. Michael also co-founded the nonprofit BiotechStart.org to facilitate the dissemination of successful business models for biotech startups, increase awareness amongst prospective founders and help start more biotech companies. Before starting Sample6 and BiotechStart, Michael completed his doctoral work on network approaches to combat antibiotic-tolerant bacteria with Professor James Collins at the Howard Hughes Medical Institute and Boston University. While working on his thesis Michael co-developed Sample6’s technology, working with Tim Lu. Michael remains a visiting scholar with the Synthetic Biology Group at MIT and HHMI in the Biomedical Engineering Department at BU. Prior to his doctoral degree, Mike graduated with a M.S. in Biochemistry from the Free University of Berlin, and was a recipient of the German Academic Exchange Fellowship (DAAD) to study at MIT. In addition to his scientific work, Mike previously worked at KPMG Consulting and McKinsey & Company in Germany, as well as Flagship Ventures in Cambridge, MA, USA.

Day 2

Martin J. Loessner, ETH Zurich, Institute of Food, Nutrition and Health, Zurich, Switzerland
Martin obtained his PhD from the Technical University of Munich 1991 and was appointed Assistant Professor for Microbiology in 1999. Since 2003, Martin Loessner is Full Professor and Chair of Food Microbiology at the Swiss Federal Institute of Technology, ETH Zurich, Switzerland. The research in his lab is focused on the molecular biology of pathogenic bacteria, and their specific bacteriophages. The aim is to derive novel and innovative applications for the detection and control of pathogenic bacteria. The work is reflected in many research papers, book chapters, reviews, and patents; and has received several awards and prizes.

Jodi A Lindsay, PhD, St George's, University of London, London, UK
Professor Jodi Lindsay specialises in the bacterial pathogen Staphylococcus aureus, a common cause of infection in humans and animals. She is particularly interested in the genetics and evolution of strains that are increasingly virulent and resistant to antibiotics, including methicillin-resistant S. aureus (MRSA). She gained her PhD from the University of Western Australia, post-doc-ed in New York and Sheffield, before joining the faculty at St George’s, University of London. She is Reviews Editor for the journal Microbiology, and sits on committees for BBSRC, ESCMID, and several conferences. She has published >80 papers and edited a book on staphylococcal genetics.

Gilbert Verbeken, Human Cell- and Tissue Banks, Queen Astrid Military Hospital, Brussels, Belgium
Gilbert Verbeken (1961) studied at Ghent University (Belgium). As a biologist, he is more than 25 years active in the field of human cell- and tissue (processing and) banking. Focusing on skin and keratinocytes. Since 1988, he is working at the Queen Astrid Military Hospital (QAMH), Brussels, Belgium. Today, next to some operational activities related to the Hospitals’ Banks, he is QA/QC/RA Manager for these Banks (Skin, Keratinocytes, Hearth Valves, and Blood Vessels). Gilbert has built up extra experience working together with biotech industry (shared projects) on “products” that are called "Advanced Therapy Medicinal Products" (ATMP) today. He is appointed expert advisor to the Belgian Superior Health Council (Human Body Material), to DG Sanco (Biological Safety) and to DG Research (Ethics). He is affiliated (scientific co-operator) to the Free University of Brussels, Belgium (VUB) and to the University of Leuven, Belgium (KU Leuven). Gilbert assisted to the recent development of the European Good Tissue Practices Guidelines (Euro GTPs). He is engaged in the (potential) launch of a Bacteriophage Therapy Centre at the QAMH, Brussels, Belgium (feasibility study) and studies the regulatory hurdles and ethical issues related to the implementation of (natural) bacteriophage therapy within Europe.

Steven Hagens, PhD, Chief Scientific Officer, The Netherlands
Steven studied molecular biology at the University of Groningen, The Netherlands. During his PhD thesis at the Institute of Microbiology and Genetics at Vienna University Austria, he worked on bacteriophage therapy of Pseudomonas aeruginosa infections. Steven went on to become a post-doctoral fellow at the Laboratory for
David P Trudil, NHDetect Corp & Eliava Institute of Bacteriophage, Reisterstown, MD, USA

David is an advisor to the Eliava Institute of Bacteriophage in Tbilisi, president of NHDetect Corp. and a director of New Horizons Diagnostics.

He has almost 40 years of experience with infectious diseases. He was the PM on ten Department of Energy/ISTC projects with former Soviet laboratories, a US Department of Defense subject matter expert and a member of the Homeland Security Detection panel. He has published and presented over 75 articles on detection, prevention and therapies; included in numerous patents; and participated on the team that developed the first rapid colloidal gold assay with use of lytic enzymes (1986).

Mireille Ansaldi, Aix Marseille Université, CNRS – Marseille, France

Mireille Ansaldi got her PhD from the Aix-Marseille University in 2000. She is now a CNRS research director and a group leader at the Laboratoire de Chimie Bactérienne, CNRS Marseille. The primary research interests of her group relate to the evolution of microbial genomes through the acquisition of prophage genes, with a particular interest in dissecting the interconnexions between prophages and bacterial genomes from an evolutionary as well as from a mechanistic point of view.

Olivia McAuliffe, Teagasc Food Research Centre, Cork, Ireland

Dr. Olivia McAuliffe is a senior research scientist at the Teagasc Food Research Centre in Cork, Ireland. Her research is mainly focused on the in-depth analysis of phages and the relationship that they have with their host cells, and understanding the molecular mechanisms underpinning phage infection. She and her colleagues are also investigating the potential of using bacteriophages and products derived from them, as therapeutics and diagnostics, targeting more problematic pathogens such as MRSA, Clostridium difficile, E. coli O157:H7 and Listeria monocytogenes. She also works closely with the dairy industry on combating phage in dairy fermentations.

Bin Zhu, Research Fellow, Harvard Medical School Boston, MA, USA

Dr. Bin Zhu received his Ph.D. degree from Chinese Academy of Sciences in 2007 and since joined Charles C. Richardson’s lab in Harvard Medical School, working on the DNA enzymes of bacteriophage T7. In a lab where T4 DNA ligase, T4 PNK, and Sequenase were invented, Dr. Zhu established interest on characterization of novel bacteriophage enzymes. Combining his passion on the ocean and the marine lives, Dr. Zhu has led the characterization of multiple novel DNA enzymes from newly sequenced marine phages. Some of them such as the Syn5 RNA polymerase have shown great potential as valuable tools for biotechnology.

Day 3

Heather E. Allison, University of Liverpool, BioSciences Building, Crown Street, Liverpool, United Kingdom

Heather Allison is a Reader in Microbiology at the University of Liverpool where she has been employed as an academic since 2001; this is the same year that she began chasing her interests in converting phages. Prior to this she had been a NIDR sponsored Postdocotral Fellow at the University of Rochester, Rochester NY.

Zuzanna Drulis-Kawa, PhD., Institute of Genetics and Microbiology, University of Wroclaw, Poland

Zuzanna is working as Associate Professor at Department of Pathogen Biology and Immunology, Institute of Genetics and Microbiology, University of Wroclaw, Poland. She is a clinical microbiologist. Her research activities focus on bacterial drug resistance, alternative antibacterial therapies including liposomes, nanomaterials, photodynamic inactivation, phage and phage-derived proteins applications. Currently she is involved in COST BM1003 Action: Microbial cell surface determinants of virulence as targets for new therapeutics in Cystic Fibrosis.

Mikael Skurnik, Ph.D., Professor of Bacteriology, University of Helsinki, Finland

Haartman Institute, Department of Bacteriology and Immunology Research Programs Unit, Immunobiology, Helsinki University Central Hospital Laboratory Diagnostics

Dr. Mikael obtained his PhD in biochemistry 1985 at University of Oulu, Finland. Postdoc 1985-7 with Hans Wolf-Watz at Umeå University, Sweden, then 1987-2002 different posts at University of Turku, Finland, and appointed as full Professor of Bacteriology at University of Helsinki in 2002. Since 1980 studied molecular biology and
genetics of microbial pathogenesis using Yersinia-bacteria as model organisms, molecular biology of Yersinia – specific bacteriophages and phage therapy. 

Magdalena Plotka, Department of Microbiology, University of Gdansk, Gdansk, Poland
Magdalena Plotka has a PhD from Intercollegiate Faculty of Biotechnology, UG&MUG, Gdansk, Poland. She is an experienced molecular microbiologist. For three years, she was a postdoctoral research assistant at the University of Oxford, Great Britain. Dr Plotka is currently a Senior Research Associate at the Department of Microbiology, University of Gdansk. During the past three years she was involved in the project “Exgenomes Molecular Enzymes” founded by EU with main interest in developing new and improving existing thermostable enzymes.

Tony Hitchcock, Technology Director, Cobra Biologics, Newcastle, UK
Tony has over 30 years of experience in the large-scale manufacture of biopharmaceuticals. Tony has held positions in the Blood Products Laboratory (Elstree) and at Zeneca Pharmaceuticals in the protein process development department. As a founding staff member of Cobra Tony has been responsible for the development of much of Cobra’s manufacturing technologies in the field of DNA and virus production.

Rok Sekirnik, BIA Separations, Slovenia
Rok Sekirnik read chemistry at University of Oxford, UK, where he also obtained his PhD. His research focus has been on developing novel liquid chromatography methods for analytical studies of large biological complexes including prokaryotic and eukaryotic ribosomes to study post-translational modifications of ribosomal proteins. At BIA Separations he is responsible for development of projects in downstream purification of therapeutic viruses and gene therapy vectors.

Discussion Sessions
The discussion sessions are an opportunity for informal questions and answers. This is an ideal opportunity to get advice and opinion from experts in this area. This session is not for questions about specific talks, which can be asked after the speakers session, but for discussing either general topics or specific issues.

Session breaks
All breaks and registrations will take place in the exhibition area where there will be lunch and refreshments.

Please try to visit all the exhibition stands during this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you.

Lunch
- All the chicken in our lunch buffet is Halal
- We have a number of dishes that are gluten free
- We have a range of vegetarian dishes which are separated from the meat and fish dishes

Frequently asked questions about our events
Is the delegate list available?
Yes this is available to everyone who attends the event and our sponsors. It is available in real time. To access the list please just log into your registration details or use the QR code on right of the agenda card which is provided on the day of the event.
You will not be included in this list if you have opted out and you can do this by logging into your registration details. This list will not be sold or ever give out to third parties.

**Can I have the speakers slides?**
We cannot give out the slides from our speaker's presentations as they are deleted immediately after each event. If you require a particular set of slides please approach the speaker. We will however have a meeting report and you will be emailed when this report is published.

**Can I have a notepad?**
Notepads and pens are provided in the delegate bags and at the registration desk

**How can I keep up to date with Euroscicon Events?**
To keep updated on our events and other Life Science News, please sign up for our newsletter at [www.eurosciconnews.com](http://www.eurosciconnews.com)

**I don’t want my photograph on any Euroscicon promotional material**
Please let our tech person know

**Is there WIFI?**
Yes, please ask registration for log in details

**Can I have a CPD certificate?**
CPD certificates will be available in the exhibition hall after lunch

Please remember that EuroSciCon is a small independent company with no subsidies from society memberships or academic rates for venues. We try to be as reasonably priced as possible and our delegate rates are substantially lower than comparable commercial meeting organisations.

*Euroscicon Ltd UK, Company Number: 4326921, Registered address: 47 Falkland Road, Herts EN5 4LQ*